J&J Lung Cancer Combo Cuts Side Effects, Extends Survival to 34.3 Months
JNJ sits 53% above its 52-week low of $173.33 on light trading volume (0.3× avg).
Summary
J&J reported two positive lung cancer datasets. The Phase 2b COPERNICUS study of subcutaneous RYBREVANT FASPRO plus LAZCLUZE showed a cleaner safety profile than the IV regimen, with only 8% discontinuing due to adverse events and low rates of rash, infusion reactions, and blood clots. The Phase 3 PAPILLON study showed the IV RYBREVANT plus chemo combination extended median overall survival to 34.3 months versus 27.9 months for chemo alone, a 6.4-month advantage, with a 43% reduction in death risk after crossover adjustment. These results strengthen J&J's lung cancer franchise and support potential label expansion for the subcutaneous formulation. The stock was down 0.74% on the day, suggesting the market had partially anticipated the data. Watch for regulatory submissions and potential FDA decisions on the subcutaneous combination.
At the time of this announcement, JNJ was trading at $264.67 on NYSE in the Life Sciences sector, with a market capitalization of approximately $637.8B. The 52-week trading range was $173.33 to $281.07. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.